S&P 500   3,386.87 (+0.19%)
DOW   27,954.87 (-0.08%)
QQQ   274.55 (+0.99%)
AAPL   461.35 (+2.06%)
MSFT   210.96 (+0.85%)
FB   263.17 (+1.26%)
GOOGL   1,528.03 (+1.38%)
AMZN   3,203.59 (+1.31%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.00 (-1.22%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
S&P 500   3,386.87 (+0.19%)
DOW   27,954.87 (-0.08%)
QQQ   274.55 (+0.99%)
AAPL   461.35 (+2.06%)
MSFT   210.96 (+0.85%)
FB   263.17 (+1.26%)
GOOGL   1,528.03 (+1.38%)
AMZN   3,203.59 (+1.31%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.00 (-1.22%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
S&P 500   3,386.87 (+0.19%)
DOW   27,954.87 (-0.08%)
QQQ   274.55 (+0.99%)
AAPL   461.35 (+2.06%)
MSFT   210.96 (+0.85%)
FB   263.17 (+1.26%)
GOOGL   1,528.03 (+1.38%)
AMZN   3,203.59 (+1.31%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.00 (-1.22%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
S&P 500   3,386.87 (+0.19%)
DOW   27,954.87 (-0.08%)
QQQ   274.55 (+0.99%)
AAPL   461.35 (+2.06%)
MSFT   210.96 (+0.85%)
FB   263.17 (+1.26%)
GOOGL   1,528.03 (+1.38%)
AMZN   3,203.59 (+1.31%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.00 (-1.22%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
Log in

NASDAQ:CLVSClovis Oncology Stock Price, Forecast & News

$4.97
+0.08 (+1.64 %)
(As of 08/13/2020 01:01 PM ET)
Add
Compare
Today's Range
$4.86
Now: $4.97
$5.09
50-Day Range
$4.90
MA: $6.38
$7.47
52-Week Range
$2.93
Now: $4.97
$17.37
Volume65,528 shs
Average Volume6.70 million shs
Market Capitalization$382.20 million
P/E RatioN/A
Dividend YieldN/A
Beta2.4
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Read More
Clovis Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.01 million
Book Value($3.17) per share

Profitability

Net Income$-400,420,000.00
Net Margins-241.69%

Miscellaneous

EmployeesN/A
Market Cap$382.20 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$4.97
+0.08 (+1.64 %)
(As of 08/13/2020 01:01 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

How has Clovis Oncology's stock price been impacted by Coronavirus?

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLVS stock has decreased by 19.8% and is now trading at $4.95.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Clovis Oncology?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Clovis Oncology
.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Clovis Oncology
.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.04) by $0.11.
View Clovis Oncology's earnings history
.

What price target have analysts set for CLVS?

8 brokerages have issued 12 month target prices for Clovis Oncology's stock. Their forecasts range from $4.00 to $33.00. On average, they anticipate Clovis Oncology's stock price to reach $11.67 in the next twelve months. This suggests a possible upside of 135.7% from the stock's current price.
View analysts' price targets for Clovis Oncology
.

Has Clovis Oncology been receiving favorable news coverage?

Press coverage about CLVS stock has been trending extremely negative on Thursday, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clovis Oncology earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about Clovis Oncology
.

Are investors shorting Clovis Oncology?

Clovis Oncology saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 26,510,000 shares, an increase of 23.8% from the April 30th total of 21,410,000 shares. Based on an average daily volume of 7,790,000 shares, the short-interest ratio is presently 3.4 days.
View Clovis Oncology's Short Interest
.

Who are some of Clovis Oncology's key competitors?

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Alibaba Group (BABA), Netflix (NFLX), Amarin (AMRN), Bristol-Myers Squibb (BMY) and Tesla (TSLA).

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the following people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (1.69%), Bank of New York Mellon Corp (0.44%), Principal Financial Group Inc. (0.33%), Macquarie Group Ltd. (0.33%), SG Americas Securities LLC (0.26%) and Swiss National Bank (0.24%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross and Thorlef Spickschen.
View institutional ownership trends for Clovis Oncology
.

Which major investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., SG Americas Securities LLC, Spark Investment Management LLC, Quilter Plc, McAdam LLC, State of Wisconsin Investment Board, and Dupont Capital Management Corp. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, and Paul Edward Gross.
View insider buying and selling activity for Clovis Oncology
.

Which major investors are buying Clovis Oncology stock?

CLVS stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Principal Financial Group Inc., Swiss National Bank, Macquarie Group Ltd., Rafferty Asset Management LLC, Bank of New York Mellon Corp, California Public Employees Retirement System, and New York State Common Retirement Fund. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen.
View insider buying and selling activity for Clovis Oncology
.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $4.95.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $380.66 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.